LEVELS OF FETAL HEMOGLOBIN NECESSARY FOR TREATMENT OF SICKLE-CELL DISEASE
LEVELS OF FETAL HEMOGLOBIN NECESSARY FOR TREATMENT OF SICKLE-CELL DISEASE
复制标题
DOI：
10.1056/nejm198801143180207
复制
发表时间：
1988-01-14
影响因子：
158.5
通讯作者：
SCHECHTER, AN
中科院分区：
文献类型：
--
作者：
NOGUCHI, CT;RODGERS, GP;SCHECHTER, AN
增加镰状细胞病和其他血红蛋白病患者γ链合成的药理学策略的出现1234567使得确定胎儿血红蛋白（血红蛋白F）水平的各种增加可能预期的益处变得重要。虽然使用氮胞苷和羟基脲等药物导致的血红蛋白F水平升高似乎是中度的（≤ 20%血红蛋白F），但这些药物的潜在毒性相对较高。幸运的是，在过去的几年里，对镰状细胞病严重程度的流行病学分析和对细胞内聚合的生物物理学研究已经导致了......
THE advent of pharmacologic strategies for increasing γ-chain synthesis in patients with sickle cell disease and other hemoglobinopathies1234567has made it important to ascertain the benefit that may be expected from various increases in fetal hemoglobin (hemoglobin F) levels. Although the increases in hemoglobin F levels resulting from the use of drugs such as azacytidine and hydroxyurea appear to be moderate (≤20 percent hemoglobin F), the potential toxicity of these drugs is relatively high. Fortunately, in the past few years, epidemiologic analyses of the severity of sickle cell disease and studies of the biophysics of intracellular polymerization have led to . . .